Global Oncology Academy

Evaluating a Treatment for HER2-Positive Metastatic Breast Cancer

Evaluating a Treatment for HER2-Positive Metastatic Breast Cancer
RestartResume

Review clinical data from the DESTINY Breast03 trial, and find out more about a new treatment option for HER2-positive metastatic breast cancer

  • Overview

    A new treatment option for breast cancer may alter the treatment landscape for patients with HER2-positive metastatic breast cancer. Joining Dr. Pavani Chalasani to share data from the DESTINY Breast03 trial is Dr. Erika Hamilton, the Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute at Tennessee Oncology.

Facebook Comments

5-Year Follow-Up Update of the MAIA Study
Charles Turck, PharmD, BCPS, BCCCP

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free